Cargando…
Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
Background: Angiotensin Converting Enzyme inhibitors (ACEis) and beta-blockers (BB) are suggested to prevent and treat trastuzumab-related cardiac toxicity. We performed a prospective clinical trial in women experiencing mild cardiac toxicity (MCT) while on adjuvant treatment with trastuzumab. Metho...
Autores principales: | Geuna, Elena, Lombardi, Pasquale, Martinello, Rossella, Garino, Davide, Bonzano, Alessandro, Galizia, Danilo, Nuzzo, Annamaria, Berchialla, Paola, Becco, Paolo, Mangioni, Monica, De Zarlo, Lorena, Montemurro, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072182/ https://www.ncbi.nlm.nih.gov/pubmed/32023877 http://dx.doi.org/10.3390/cancers12020327 |
Ejemplares similares
-
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
por: Galizia, Danilo, et al.
Publicado: (2018) -
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021) -
Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015) -
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
por: Redana, Stefania, et al.
Publicado: (2010) -
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)